SynthesisJournal of the National Cancer Institute2015
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
Synthesis in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.Frontiers in oncology · 2021Pooled it
- Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Journal for immunotherapy of cancer · 2019Trial
- Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.Chinese journal of cancer · 2017Trial
- Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.JAMA network open · 2026Article
- Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.Oncology and therapy · 2025Article
- A call for objectivity: Radiologists' proposed wishlist for response evaluation in solid tumors (RECIST 1.1).Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment.Cancer letters · 2023Article
- Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials.Contemporary clinical trials communications · 2021Article
- A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.Radiology. Imaging cancer · 2021Article
- Response criteria for intraocular retinoblastoma: RB-RECIST.Pediatric blood & cancer · 2021Article
- Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.PloS one · 2021Article
- Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials.Contemporary clinical trials communications · 2020Article
- Cancer cell population growth kinetics at low densities deviate from the exponential growth model and suggest an Allee effect.PLoS biology · 2019Article
- Observational
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.European journal of nuclear medicine and molecular imaging · 2017Review
- On the relationship between tumour growth rate and survival in non-small cell lung cancer.PeerJ · 2017Article
- Time to progression ratio: promising new metric or just another metric?Annals of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWe sought to develop and validate clinically relevant, early assessment continuous tumor measurement-based metrics for predicting overall survival (OS) using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 data warehouse.
methodsData from 13 trials representing 2096 patients with breast cancer, non-small cell lung cancer (NSCLC), or colorectal cancer were used in a complete case analysis. Tumor measurements from weeks 0-6-12 assessments were used to evaluate the ability of slope (absolute change in tumor size from 0-6 and 6-12 weeks) and percent change (relative change in tumor size from 0-6 and 6-12 weeks) metrics to predict OS using Cox models, adjusted for average baseline tumor size. Metrics were evaluated by discrimination (via concordance or c-index), calibration (goodness-of-fit type statistics), association (hazard ratios), and likelihood (Bayesian Information Criteria), with primary focus on the c-index. All statistical tests were two-sided.
resultsComparison of c-indices suggests slight improvement in predictive ability for the continuous tumor measurement-based metrics vs categorical RECIST response metrics, with slope metrics performing better than percent change metrics for breast cancer and NSCLC. However, these differences were not statistically significant. The goodness-of-fit statistics for the RECIST metrics were as good as or better than those for the continuous metrics. In general, all the metrics performed poorly in breast cancer, compared with NSCLC and colorectal cancer.
conclusionAbsolute and relative change in tumor measurements do not demonstrate convincingly improved overall survival predictive ability over the RECIST model. Continued work is necessary to address issues of missing tumor measurements and model selection in identifying improved tumor measurement-based metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.